Remarkable extension of PAI-1 half-life surprisingly brings no changes to its structure

International Journal of Molecular Medicine

Volumn 29, Issue 1, 2012, Pages 61-64

  Jankun, Jerzy ^a,c,d   Yang, Jie ^b   Zheng, Hong ^b   Han, Frank Q ^b   Al Senaidy, Abdulrahman ^d   Skrzypczak Jankun, Ewa ^a  

^a MEDICAL COLLEGE OF OHIO   (United States)

^b Structure Based Design Inc   (United States)

^c MEDICAL UNIVERSITY OF GDANSK   (Poland)

^d KING SAUD UNIVERSITY   (Saudi Arabia)

Author keywords

Disulfide bridge; Plasminogen activator inhibitor type 1; Therapy

Indexed keywords

MUTANT PROTEIN; PLASMINOGEN ACTIVATOR INHIBITOR 1; RECOMBINANT PROTEIN; RECOMBINANT VERY LONG HALF LIFE PLASMINOGEN ACTIVATOR INHIBITOR 1; UNCLASSIFIED DRUG;

AMINO ACID SEQUENCE; AMINO TERMINAL SEQUENCE; ANIMAL CELL; ARTICLE; CRYSTAL STRUCTURE; DISULFIDE BOND; DRUG HALF LIFE; DRUG STRUCTURE; GLYCOSYLATION; HYDROGEN BOND; NONHUMAN; PRIORITY JOURNAL; STRUCTURE ANALYSIS; WILD TYPE;

ANIMALS; CELL LINE; CRYSTALLOGRAPHY, X-RAY; DISULFIDES; GLYCOSYLATION; HUMANS; MICE; MODELS, MOLECULAR; MUTATION; PLASMINOGEN ACTIVATOR INHIBITOR 1; POLYSACCHARIDES; PROTEIN STABILITY; RECOMBINANT PROTEINS;

EID: 84855177592     PISSN: 11073756     EISSN: 1791244X     Source Type: Journal    
DOI: 10.3892/ijmm.2011.798     Document Type: Article

References (22)

1. Chorostowska-Wynimko J, Swiercz R, Skrzypczak-Jankun E, Wojtowicz A, Selman SH and Jankun J: A novel form of the plasminogen activator inhibitor created by cysteine mutations extends its half-life: relevance to cancer and angiogenesis. Mol Cancer Ther 2: 19-28, 2003.
2. Stout TJ, Graham H, Buckley DI and Matthews DJ: Structures of active and latent PAI-1: a possible stabilizing role for chloride ions. Biochemistry 39: 8460-8469, 2000. (Pubitemid 30489942)
3. Tucker HM, Mottonen J, Goldsmith EJ and Gerard RD: Engineering of plasminogen activator inhibitor-1 to reduce the rate of latency transition. Nat Struct Biol 2: 442-445, 1995.
4. Zhou A, Huntington JA, Pannu NS, Carrell RW and Read RJ: How vitronectin binds PAI-1 to modulate fibrinolysis and cell migration. Nat Struct Biol 10: 541-544, 2003. (Pubitemid 36792905)
5. Nar H, Bauer M, Stassen JM, Lang D, Gils A and Declerck PJ: Plasminogen activator inhibitor 1. Structure of the native serpin, comparison to its other conformers and implications for serpin inactivation. J Mol Biol 297: 683-695, 2000.
6. Lin Z, Jiang L, Yuan C, et al.: Structural basis for recognition of urokinase-type plasminogen activator by plasminogen activator inhibitor-1. J Biol Chem 286: 7027-7032, 2011.
7. Blouse GE, Perron MJ, Kvassman JO, et al.: Mutation of the highly conserved tryptophan in the serpin breach region alters the inhibitory mechanism of plasminogen activator inhibitor-1. Biochemistry 42: 12260-12272, 2003. (Pubitemid 37296503)
8. Jensen JK, Thompson L, Nissen P, et al.: Crystal structure of plasminogen activator inhibitor-1 in an active conformation with normal thermodynamic stability. J Biol Chem: Jun 21, 2011 (Epub ahead of print).
9. Xue Y, Bjorquist P, Inghardt T, et al.: Interfering with the inhibitory mechanism of serpins: crystal structure of a complex formed between cleaved plasminogen activator inhibitor type 1 and a reactive-centre loop peptide. Structure 6: 627-636, 1998. (Pubitemid 28258115)
10. Jankun J, Aleem AM, Selman SH, Basrur V and Skrzypczak- Jankun E: VLHL plasminogen activator inhibitor spontaneously reactivates from the latent to active form. Int J Mol Med 23: 57-63, 2009.
11. Lee HJ and Im H: Purification of recombinant plasminogen activator inhibitor-1 in the active conformation by refolding from inclusion bodies. Protein Expr Purif 31: 99-107, 2003.
12. Otwinowski Z and Minor W: Processing of X-ray diffraction data collected in oscillation mode. Methods Enzymol 276: 307-326, 1997. (Pubitemid 27085611)
13. Collaborative Computational Project Number 4, The CCP suite: programs for protein crystallography. Acta Crystallogr D Biol Crystallogr 50: 760-763, 1994.
14. Emsley P and Cowtan K: Coot: model-building tools for molecular graphics. Acta Crystallogr D Biol Crystallogr 60: 2126-2132, 2004. (Pubitemid 41742764)
15. DeLano WL: The PyMOL Molecular Graphics System (2002). DeLano Scientific, San Carlos, CA, USA. Available from, http://www.pymol.org.
16. DeLano WL: The case for open-source software in drug discovery. Drug Discov Today 10: 213-217, 2005.
17. Krissinel E and Henrick K: Multiple alignment of protein structures in three dimensions. CompLife LNBI 3695: 67-78, 2005.
18. De Taeye B, Gils A and Declerck PJ: The story of the serpin plasminogen activator inhibitor 1: is there any need for another mutant? Thromb Haemost 92: 898-924, 2004. (Pubitemid 39545512)
19. Rendić D, Wilson IBH and Paschinger K: The glycosylation capacity of insect cells. Croatica Chemica Acta 81: 7-21, 2008.
20. Jankun J, Aleem AM, Specht Z, et al.: PAI-1 induces cell detachment, downregulates nucleophosmin (B23) and fortilin (TCTP) in LnCAP prostate cancer cells. Int J Mol Med 20: 11-20, 2007.
21. Jankun J, Selman SH, Keck RW, Lysiak-Szydlowska W and Skrzypczak-Jankun E: Very long half-life plasminogen activator inhibitor type 1 reduces bleeding in a mouse model. BJU Int 105: 1469-1476.
22. Swiercz R, Keck RW, Skrzypczak-Jankun E, Selman SH and Jankun J: Recombinant PAI-1 inhibits angiogenesis and reduces size of LNCaP prostate cancer xenografts in SCID mice. Oncol Rep 8: 463-470, 2001.